PIPELINE

MINI-001

MINI-003

MINI-004

MINI-012

Phase II - Sept 2023 / Phase III - 2023

Follistatin is a morphogenetic protein with a broad range of effects including the capacity to inhibit myostatin in a tissue specific manner. Follistatin is a candidate for multiple therapeutic modalities.

Discovery & Preclinical Development - Candidate

Testosterone is a master regulator hormone controlling self-confidence, risk-taking behavior, emotional stability, body composition, rational thinking, cognitive well-being, and libido. Low testosterone levels are endemic in modern civilization where sedentary lifestyles are common and industrial hyperestrogenic compounds are constantly consumed in air, water, and food.

Discovery & Preclinical Development - Candidate

Discovery & Preclinical Development - Candidate

MINI-002

MINI-006

MINI-007

MINI-008

Clinical Development - Phase I

Our innovative HIV plasmid therapy constantly delivers human origin broadly neutralizing antibodies discovered by the US National Institutes of Health. This therapy is designed to be distributed in high temperature climates like Africa, India, and Central America and does not require refrigeration. Our hope is that this therapy can be proven both as a “functional cure” for HIV as well as a safe and effective prophylactic designed for global eradication of HIV.

Discovery & Preclinical Development - Lead

Our herpes gene therapy will work similarly to our HIV gene therapy. Broadly neutralizing antibodies that bind to HSV 1 & 2 can be constantly produced and secreted into the bloodstream in hopes of eliminating the transmission and symptoms of HSV.

Discovery & Preclinical Development - Candidate

Our innovative therapy for Crohn’s disease uses plasmids to deliver TNF-alpha neutralizing antibodies at a constant rate for 1-2 years. This therapy, if successful should be able to replace the functionality of existing biologics.

Discovery & Preclinical Development - Candidate

A combination of antibodies and morphogenetic proteins can be delivered to create an expected 25% decrease in body fat with a single injection.